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Abstract: The objective was to investigate the incidence of thromboembolic stroke in patients 
with chronic kidney disease (CKD) and atrial fibrillation (AF) treated with and without warfarin. 
We investigated the incidence of thromboembolic stroke and of major bleeding in 399 unselected 
patients with CKD and AF treated with warfarin to maintain an international normalized ratio 
(INR) between 2.0 and 3.0 (N = 232) and without warfarin (N = 167). Of the 399 patients, 
93 (23%) were receiving hemodialysis, and 132 (33%) had an estimated glomerular filtration 
rate (GFR) of 15 mL/min/1.73 m2 At the 31-month follow-up of patients treated with warfarin 
and 23-month follow-up of patients not treated with warfarin, thromboembolic stroke developed 
in 21 of 232 patients (9%) treated with warfarin and in 43 of 167 patients (26%) not treated 
with warfarin (P  0.001). Major bleeding occurred in 32 of 232 patients (14%) treated with 
warfarin and in 15 of 167 patients (9%) not treated with warfarin (P not significant). Stepwise 
Cox regression analysis showed that significant independent predictors of thromboembolic stroke 
were use of warfarin (odds ratio, 0.28; P  0.0001) and prior stroke or transient ischemic attack 
(odds ratio, 2.9; P  0.05). In conclusion, this observational study showed that CKD patients 
with AF treated with warfarin to maintain an INR between 2.0 and 3.0 had a significant reduction 
in thromboembolic stroke and an insignificant increase in major bleeding.
Keywords: chronic kidney disease, atrial fibrillation, anticoagulants, thromboembolic stroke, 
major bleeding
Introduction
Chronic kidney disease (CKD) is associated with an increased prevalence and 
incidence of atrial fibrillation (AF).1–6 The prevalence of AF in persons with CKD 
was 7%,1 11%,2 14%,3 19%,4 23%,5 and 27%.6 Vazquez and colleagues reported 
that 26 of 190 hemodialysis patients (14%) had AF at baseline.3 At one-year 
follow-up, AF was the only independent predictor of thromboembolic events (odds 
ratio [OR], 8.03; 95% confidence interval [CI]: 2.35–27.4).3 During the 50-month 
follow-up, Vazquez and colleagues reported that 11 of the 26 patients (42.3%) with 
AF had 14 thromboembolic events while thromboembolic events occurred in 9.7% 
of the 164 patients with sinus rhythm at baseline (relative risk [RR], 4.6; 95% CI: 
2.4–8.6) in unadjusted analyses.7 During a mean follow-up period of 47 months, 
20 of the 164 hemodialysis patients (12%) without AF at baseline developed AF. 
Those who developed AF had a significant increase in subsequent thromboembolic 
events (RR, 5.2; 95% CI: 2.1–12.4).8International Journal of Nephrology and Renovascular Disease 2009:2 34
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In the general population, numerous prospective, 
randomized, double-blind, placebo-controlled trials9–18 
and prospective, nonrandomized observational data19–21 
have shown that high-risk patients with nonvalvular AF 
treated with warfarin to maintain an international normal-
ized ratio (INR) between 2.0 and 3.0 have a significant 
decrease in thromboembolic stroke with an acceptable 
risk of  bleeding.9–21 At 1.1-year follow-up in the Stroke 
Prevention and Atrial Fibrillation (SPAF) Study III, patients 
with AF considered to be at high risk for developing new 
thromboembolic stroke who were randomized to treatment 
with oral warfarin to achieve an INR between 2.0 and 
3.0 had a 72% significant decrease in ischemic stroke or 
systemic embolism compared with patients randomized to 
treatment with oral aspirin 325 mg daily plus oral warfarin 
to achieve an INR between 1.2 and 1.5.11 Adjusted-dose 
warfarin caused an absolute decrease in ischemic stroke 
or systemic embolism of 6.0% per year.11
However, all of these clinical trials8–21 have excluded 
patients with late-stage CKD. It is essential that prospective, 
double-blind, placebo-controlled trials be performed in 
patients with late-stage CKD and AF to determine the 
efficacy of oral anticoagulant therapy in preventing throm-
boembolic events and the incidence and type of hemorrhagic 
events.22 The present study reports a retrospective analysis 
of the incidence of thromboembolic stroke and of major 
bleeding in 399 patients with CKD and AF treated 
with warfarin to maintain an INR between 2.0 and 3.0 
(232 patients) versus no warfarin (167 patients) by the 
nephrologists at Westchester Medical Center/New York 
Medical College.
Methods
In an observational retrospective study, we reviewed all 
charts for the incidence of thromboembolic events and of 
major bleeding in all patients with CKD and nonvalvular 
AF treated with and without warfarin by the nephrolo-
gists at Westchester Medical Center/New York Medical 
College. No patients were excluded from the analysis. Of the 
399 patients with CKD, 93 (23%) were receiving hemodi-
alysis, 132 (33%) had an estimated glomerular filtration rate 
(GFR)  15 mL/min/1.73 m2, 67 (17%) had an estimated 
GFR between 15–29 mL/min/1.73 m2, and 200 (50%) had 
an estimated GFR between 30–59 mL/min/1.73 m2. The 
estimated GFR was calculated by the Modification of Diet 
in Renal Disease study equation.23,24 The charts were also 
analyzed for all of the variables listed in Table 1.
The dose of warfarin used was adjusted to maintain 
an INR between 2.0 and 3.0. The dose of aspirin used was 
81 mg daily.
Table 1 Baseline characteristics for patients with chronic kidney disease and atrial fibrillation treated with and without warfarin
Variable Warfarin (N = 232) No warfarin (N = 167) P  value
Women 67 (29%) 61 (37%) Not significant
Men 165 (71%) 106 (63%) Not significant
Age (years) 73 ± 12 77 ± 11 0.001
gFR 30–59 mL/min/1.73 m2 115 (50%) 85 (51%) Not significant
gFR 15–29 mL/min/1.73 m2 39 (17%) 28 (17%) Not significant
gFR  15 mL/min/1.73 m2 78 (34%) 54 (32%) Not significant
hemodialysis 51 (22%) 42 (25%) Not significant
Renal transplant 15 (6%) 5 (3%) Not significant
Aspirin 92 (40%) 73 (44%) Not significant
Prior stroke or TIA 19 (8%) 13 (8%) Not significant
coronary artery disease 145 (63%) 103 (62%) Not significant
Valvular heart disease 46 (20%) 23 (14%) Not significant
Peripheral arterial disease 15 (6%) 19 (11%) Not significant
smoking 64 (28%) 42 (25%) Not significant
hypertension 148 (64%) 114 (68%) Not significant
Diabetes mellitus 108 (47%) 66 (40%) Not significant
Dyslipidemia 156 (67%) 109 (65%) Not significant
Follow-up (months) 31 ± 34 23 ± 30 0.01
Abbreviations: GFR, estimated glomerular filtration rate;    TIA, transient ischemic attack.International Journal of Nephrology and Renovascular Disease 2009:2 35
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Student’s t-tests were used to analyze continuous variables 
between the warfarin and no warfarin groups. Chi-squared 
tests and Fisher’s exact tests were used to analyze dichoto-
mous variables between the warfarin and no warfarin 
groups. Stepwise Cox regression analysis was performed 
for thromboembolic stroke using all of the variables listed 
in Table 1.
The institutional review boards of Westchester Medical 
Center and of New York Medical College approved this 
study.
Results
Table 1 lists 18 variables for patients treated with and 
without warfarin. Table 1 also lists levels of statistical 
significance.
Table 2 shows the incidence of thromboembolic 
stroke and of major bleeding in patients treated with and 
without warfarin. Table 2 also lists levels of statistical 
significance. No thromboembolic events other than throm-
boembolic stroke were observed during this study. Of the 
21 thromboembolic strokes that occurred on warfarin, 
nine (43%) occurred when the INR was 2.0. Computed 
tomographic brain scans or magnetic resonance imaging 
were performed in 60 of the 64 thromboembolic strokes 
(94%) diagnosed clinically and confirmed the presence 
of thromboembolic stroke in 60 of 60 patients (100%). 
Computed tomographic brain scans or magnetic resonance 
imaging also showed that 14 other patients had intrace-
rebral bleeding.
Table 3 shows the stepwise Cox regression analysis 
for thromboembolic stroke. Significant independent pre-
dictors of thromboembolic stroke were prior stroke or 
transient ischemic attack (OR = 2.9) and use of warfarin 
(OR = 0.28).
Table 4 shows the incidence of thromboembolic 
stroke for patients treated with and without warfarin 
who were receiving hemodialysis, who had an estimated 
GFR  15 mL/min/1.73 m2, who had an estimated GFR 
between 15–29 mL/min/1.73 m2, and who had an estimated 
GFR between 30–59 mL/min/1.73 m2. Table 4 also lists levels 
of statistical significance.
Table 5 shows the types of major bleeding episodes in 
patients treated with and without warfarin. No significant 
differences were found between the two groups.
Discussion
In an observational study of patients with AF and a high 
proportion of CKD undergoing percutaneous coronary 
intervention with stent implantation, age (P  0.01) and 
nonanticoagulation (P = 0.02) were independent predic-
tors of death, acute myocardial infarction, or target vessel 
revascularization in patients with AF.25 However, there was 
a borderline significant finding that persons with chronic 
renal failure (undefined by the authors) were less likely 
to be anticoagulated at discharge, making it difficult to 
draw any conclusions regarding patients with CKD from 
this paper.25
In an observational study analyzing US Renal Data 
Service DMMS Wave (Dialysis Morbidity and Mortality 
Wave 2 Study) data, 123 persons were hospitalized for AF, 
and 90 (73%) died by the 2.92-year follow-up.26 Among 
these persons, only use of warfarin and systolic blood 
pressure higher than 130 mm Hg were associated with 
increased survival.
Many physicians consider CKD a condition that causes 
a high risk of bleeding complications in patients given 
warfarin for AF and are unwilling to prescribe warfarin 
for this indication.27 However, this viewpoint has been 
challenged.28–30 In a small study of hemodialysis patients 
followed for 20 months, hemorrhagic events occurred 
in 31% of 29 patients (seven with AF) receiving oral 
anticoagulants and 14% of 211 patients not receiving 
oral anticoagulants.29 None of the patients receiving oral 
Table 2 Incidence of thromboembolic stroke and of major bleeding 
during follow-up of patients with chronic kidney disease with atrial 
fibrillation treated with and without warfarin
Variable  Warfarin 
(N = 232)
No warfarin  
(N = 167)
P  value 
New stroke 21 (9%) 43 (26%) 0.001
Major bleeding 32 (14%) 15 (9%) Not significant
Table 3 stepwise cox regression analysis for thromboembolic stroke
Parameter Coefficient Standard error P  value Odds ratio 95% Confidence interval
Warfarin -1.2765 0.2927 0.0001 0.2790 0.1572, 0.4952
Prior stroke or  TIA 1.0566 0.4277 0.05 2.8766 1.2439, 6.6520
Abbreviation:  TIA, transient ischemic attack.International Journal of Nephrology and Renovascular Disease 2009:2 36
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anticoagulants developed a fatal hemorrhage, intracranial 
hemorrhage, or serious clinical sequelae.29 In a review of 
warfarin use in hemodialysis patients, Elliott and colleagues 
noted major bleeding rates varying from 0.1 to 0.54 events 
per patient-year of warfarin exposure and stressed that the 
true bleeding risk associated with the use of warfarin in 
hemodialysis patients remains unknown, given the reliance 
on small observational studies with potential confounding 
by comorbid conditions.31
Quinn and colleagues examined the issue of antico-
agulation for AF of hemodialysis patients in a cost–utility 
analysis.32 At a threshold of $100,000 per quality-adjusted 
life-year, the probabilities that no therapy, aspirin, or warfarin 
was the most efficient therapy were 20%, 23%, and 58%, 
respectively.32 An editorial accompanying this paper recom-
mended that until more data are available, anticoagulation 
should be considered in hemodialysis patients with AF, 
adhering to screening and monitoring as in the general 
population.33
The data from the present observational study of 
399 unselected patients with CKD and AF including 
93 patients on hemodialysis and 132 with an estimated 
GFR  15 mL/min/1.73 m2 showed that the incidence of 
new thromboembolic stroke was 9% at 31-month follow-up 
for 232 patients treated with warfarin and 26% at 23-month 
follow-up for 167 patients not treated with warfarin 
(P  0.001). Stepwise Cox regression analysis showed 
that significant independent predictors of new thromboem-
bolic stroke were prior stroke or transient ischemic attack 
(OR, 2.9; 95% CI: 1.2–6.6) and use of warfarin (OR, 0.28; 
95% CI: 0.16–0.50). Warfarin significantly reduced the 
incidence of new thromboembolic stroke in patients 
receiving hemodialysis (10% versus 38%) (P  0.005), 
in patients with an estimated GFR  15 mL/min/1.73 m2 
(10% versus 37%) (P  0.001), in patients with an esti-
mated GFR of 15–29 mL/min/1.73 m2 (5% versus 21%) 
(P  0.05), and in patients with an estimated GFR of 
30–59 mL/min/1.73 m2 (10% versus 20%) (P  0.05).
The data from the present study also showed that 
episodes of major bleeding occurred in 32 of 232 patients 
(14%) treated with warfarin versus 15 of 167 patients (9%) 
not treated with warfarin (P not significant). The types of 
major bleeding episodes were not significantly different 
between patients treated with and without warfarin.
The major limitation of this study is that it was not a 
prospective, randomized, double-blind, placebo-controlled 
study investigating the incidence of thromboembolic 
stroke and of major bleeding in patients with CKD and 
AF treated with warfarin versus placebo. Because of 
the high prevalence of AF and its association with an 
increased incidence of thromboembolic events in patients 
with late-stage CKD, it is essential that prospective, 
randomized, double-blind, placebo-controlled trials be 
performed in these patients to determine the efficacy of 
oral anticoagulant therapy in preventing thromboembolic 
events and the incidence and type of hemorrhagic events. 
Data from the present observational study favor treating 
patients with CKD and AF including those with late-stage 
CKD with warfarin on an individual basis, taking into 
account both the thromboembolism risk as well as the 
hemorrhagic risk.
Table 4 Incidence of thromboembolic stroke for different 
glomerular filtration rates and for hemodialysis patients treated 
with and without warfarin
Variable Warfarin No warfarin P  value
hemodialysis patients 5/51 (10%) 16/42 (38%) 0.005
gFR  15 mL/min/1.73 m2 8/78 (10%) 20/54 (37%) 0.001
gFR 15–29 mL/min/1.73 m2 2/39 (5%) 6/28 (21%) 0.05
gFR 30–59 mL/min/1.73 m2 11/115 (10%) 17/85 (20%) 0.05
Abbreviation: GFR, estimated glomerular filtration rate.
Table 5  Types of major bleeding episodes in patients treated with and without warfarin
Major bleeding episode Warfarin (N = 32) No warfarin (N = 15) P  value
Transfusion for gastrointestinal bleeding 11 (34%) 6 (40%) Not significant
Intracerebral bleeding 11 (34%) 3 (20%) Not significant
Transfusion for hemoptysis 3 (9%) 0 (0%) Not significant
Transfusion for retroperitoneal hematoma 3 (9%) 1 (7%) Not significant
Transfusion for intraperitoneal bleeding 2 (6%) 0 (0%) Not significant
Transfusion for bleeding of unknown cause 2 (6%) 3 (20%) Not significant
Transfusion for abdominal wall hematoma 0 (0%) 1 (7%) Not significant
Transfusion for pelvic hemorrhage 0 (0%) 1 (7%) Not significantInternational Journal of Nephrology and Renovascular Disease 2009:2
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